Taltz vs Otezla
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| US Taltz | US Otezla | |
|---|---|---|
| Generic name | ixekizumab | apremilast |
| Drug class | IL-17A Inhibitor (Biologic) | PDE4 Inhibitor |
| Treats | Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis | Plaque psoriasis, psoriatic arthritis, Behçet's disease |
| Category | Autoimmune | Autoimmune |
| Manufacturer | Eli Lilly | Amgen |
| Year approved | 2016 | 2014 |
| FDA warning | Moderate warnings | No boxed warning |
| Est. TV ad spend | $190M | $110M |
| Common side effects | Injection site reactions, Respiratory infections, Inflammatory bowel disease, Low white blood cell count | Diarrhea, Nausea, Headache, Weight loss |
Frequently asked questions
Is Taltz or Otezla better?
Neither is universally "better." Taltz (ixekizumab) and Otezla (apremilast) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Taltz and Otezla?
Taltz is a IL-17A Inhibitor (Biologic) made by Eli Lilly, while Otezla is a PDE4 Inhibitor made by Amgen. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Taltz has the larger estimated TV advertising budget of the two.